Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.08M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Cellectar Biosciences, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 30 | 32 | +2 |
| Shares | 5.10M | 5.21M | +109.2K (+2.1%) |
| Value | $1.52M | $1.63M | +$104.1K (+6.8%) |
New holders (8)
Institutions that held Cellectar Biosciences, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 343,258 | $108.2K | 0.00% |
| Baader Bank INC | 172,940 | $43.1K | 0.00% |
| HRT Financial LP | 46,236 | $14.0K | 0.00% |
| Rochester Wealth Strategies, LLC | 43,000 | $13.6K | 0.01% |
| Nordwand Advisors, LLC | 20,000 | $6.31K | 0.00% |
| JustInvest LLC | 17,587 | $5.54K | 0.00% |
| Commerce Bank | 10,000 | $3.15K | 0.00% |
| EverSource Wealth Advisors, LLC | 1,646 | $519 | 0.00% |
Sold out (6)
Institutions that held Cellectar Biosciences, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Altium Capital Management LP | 215,000 | $64.3K |
| Two Sigma Securities, LLC | 51,952 | $15.5K |
| BNP Paribas Arbitrage, SA | 16,815 | $5.03K |
| BFSG, LLC | 1,000 | $299 |
| Citigroup Inc | 660 | $197 |
| EnRich Financial Partners LLC | 102 | $30 |